Edwards Lifesciences (EW) Stock Price, News & Analysis

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 2 sell ratings, 9 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares.
View EW analyst ratings or view top-rated stocks.

18 brokerages have issued 1-year target prices for Edwards Lifesciences' shares. Their EW share price targets range from $57.00 to $107.00. On average, they predict the company's share price to reach $81.94 in the next year. This suggests a possible upside of 7.5% from the stock's current price.
View analysts price targets for EW or view top-rated stocks among Wall Street analysts.

Edwards Lifesciences' stock was trading at $74.61 at the start of the year. Since then, EW shares have increased by 2.2% and is now trading at $76.25.
View the best growth stocks for 2023 here.

Edwards Lifesciences saw a increase in short interest in the month of December. As of December 15th, there was short interest totaling 13,540,000 shares, an increase of 34.7% from the November 30th total of 10,050,000 shares. Based on an average trading volume of 4,770,000 shares, the short-interest ratio is presently 2.8 days. Currently, 2.3% of the company's stock are sold short.
View Edwards Lifesciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, January 30th 2024.
View our EW earnings forecast.

Edwards Lifesciences Co. (NYSE:EW) issued its earnings results on Wednesday, October, 25th. The medical research company reported $0.59 earnings per share for the quarter, hitting analysts' consensus estimates of $0.59. The medical research company earned $1.48 billion during the quarter, compared to the consensus estimate of $1.48 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 24.54% and a net margin of 24.59%. The company's quarterly revenue was up 12.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.61 EPS.
Read the conference call transcript.

ETFs with the largest weight of Edwards Lifesciences (NYSE:EW) stock in their portfolio include iShares U.S. Medical Devices ETF (IHI), Neuberger Berman Disrupters ETF (NBDS), Global X Aging Population ETF (AGNG), First Trust Indxx Medical Devices ETF (MDEV), ETC 6 Meridian Quality Growth ETF (SXQG), BNY Mellon Sustainable US Equity ETF (BKUS), Goldman Sachs Future Health Care Equity ETF (GDOC) and Inspire 100 ETF (BIBL).

Shares of Edwards Lifesciences split on the morning of Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were distributed to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

Edwards Lifesciences issued an update on its FY 2024 earnings guidance on Monday, December, 11th. The company provided earnings per share guidance of 2.700-2.800 for the period, compared to the consensus estimate of 2.800. The company issued revenue guidance of $6.3 billion-$6.6 billion, compared to the consensus revenue estimate of $6.5 billion.

389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.